Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limited

Nobuhiro Suzuki

Shuichi Furuya

Takashi Imada

Shiro Takekawa

Nobuo Choh

Takenori Hitaka

Kazuhiro Miwa

Chieko Kitada

Yuji Ishihara

Masami Kusaka

Nobuo Cho

Hirokazu Matsumoto

Jun Terauchi

Masataka Harada

Masaaki Mori

Kaneyoshi Kato

Kazunori Nishi

Kazuyoshi Aso

Kazuhiro Ogi

Yukio Shimomura

Yasuaki Itoh

Hideki Kizawa

Yoshi Nara

Asano Odaka

Shuji Hinuma

Tsuneo Yasuma

Makoto Kamata

Takashi Miki

Satoshi Endo

Koichi Kondo

Yoshihiro Banno

Shinobu Sasaki

Masami Suzuki

Tsukasa Sugo

Satoru Oi

Yoshihiro Ishibashi

Yasuaki Ito

Kohji Fukatsu

Masao Tsuda

Koki Kato

Hiroshi Mabuchi

Tomoko Asakawa

Yoji Hayase

Osamu Kataoka

Masami Kusuka

The present invention provides a compound represented by the formula: wherein Ris a Calkyl; Ris (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1') a halogen, (2&#x2032;) a hydroxy group, (3&#x2032;) a Calkyl and (4&#x2032;) a Calkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1&#x2032;) a halogen, (2&#x2032;) a Calkoxy-Calkyl, (3&#x2032;) a mono-Calkyl-carbamoyl-Calkyl, (4&#x2032;) a Calkoxy and (5&#x2032;) a mono-Calkylcarbamoyl-Calkoxy, or the like; Ris a Calkyl; Ris a Calkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.

Thienopyrimidine compounds and use thereof

Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof

The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

Receptor function regulator

The present invention relates to a therapeutic agent for diabetes with sulfonylurea secondary failure, which contains a GPR40 agonist. According to the present invention, a therapeutic agent for diabetes with sulfonylurea secondary failure that affords a superior insulin secretion effect and a superior hypoglycemic effect even in diabetic patients for whom a sulfonylurea compound or a fast-acting insulin secretagogue fails to provide an insulin secretion effect and therefore, fails to provide a sufficient hypoglycemic effect can be provided.

Remedy for diabetes

The present invention provides a thienopyrimidine compound, represented by the formula  [wherein, Ris Calkyl, Ris (1) phenyl optionally having a substituent such as amino, mono Calkylamino and di Calkylamino, or (2) a heterocyclic group optionally having a substituent such as amino, mono Calkylamino and di Calkylamino and the like, Ris a hydrogen atom or Calkyl, Ris Calkyl optionally having a substituent such as Calkoxy-carbonyl, carboxyl, mono Calkylamino and N&#x2014;Calkyl-N&#x2014;Caralkylamino and the like] or a salt thereof, which has antagonistic action for gonadotropin-releasing hormone.

Thienopyrimidines, process for preparing the same and use thereof

The present invention relates to antibodies that bind to the A chain N-terminal peptide. The present invention also relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt., (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.

Antibodies to insulin/IGF/relaxin family polypeptides

A melanin-concentrating hormone antagonist comprising a compound of the formula: wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; Rand Rare the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or Rand R, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.

Melanin-concentrating hormone antagonist

A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein

Quinoline compound

Compounds of a formula: wherein Ring A represents an optionally-substituted aromatic ring; Ring B represents an optionally-substituted cyclic hydrocarbon group; Z represents an optionally-substituted cyclic group; Rrepresents a hydrogen atom, an optionally-substituted hydrocarbon group, an optionally-substituted heterocyclic group, or an acyl group; Rrepresents an optionally-substituted amino group; D represents a chemical bond or a divalent group; E represents &#x2014;CO&#x2014;, &#x2014;CON(R)&#x2014;, COO&#x2014;, N(R)CON(R)&#x2014;, &#x2014;N(R)COO&#x2014;, &#x2014;N(R)SO&#x2014;, N(R)&#x2014;, &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014; or &#x2014;SO&#x2014; (in which Rand Reach independently represent a hydrogen atom or an optionally-substituted hydrocarbon group); G represents a chemical bond or a divalent group; L represents (1) a chemical bond or (2) a divalent hydrocarbon group optionally having from 1 to 5 substituents selected from;

Aromatic amine derivatives, their production and use

A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Aris a cyclic group which may have substituents;

Melanin concentrating hormone antagonist

The present invention relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt, (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.

Insulin/IGF/relaxin family polypeptides and DNAS thereof

The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist which can be used not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, and the like, and an SLC-1 antagonist which can be used not only as an antiobestic agents (drug), an appetite (eating) modulator, and the like, but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Wili syndrome and the like.

Antiobestic agents methods for screening antiobestic agents and kits comprising same

A melanin-concentrating hormone antagonist comprising a compound of the formula (I):wherein Aris a cyclic group which may be substituted; X and Y are the same or different and are a spacer having a main chain of 1 to 6 atoms; Ar is a condensed polycyclic aromatic ring which may be substituted; Rand Rare the same or different and are hydrogen atom or a hydrocarbon group which may be substituted; or Rand R, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or R, together with the adjacent nitrogen atom, Y and Ar, may form a condensed ring; or a salt thereof is useful as an agent for preventing or treating obesity, etc.

Growing community of inventors

Tsukuba, Japan

Nobuhiro Suzuki